Strand Life Sciences develops prenatal genomic diagnostics portfolio
Bengaluru, April 23 -- Strand Life Sciences, a subsidiary of Reliance Industries Ltd, and a leading global provider of genomic and bioinformatic solutions, announced its prenatal screening and diagnostics portfolio with two breakthrough technologies--CNSeq (for identification of aneuploidies and copy number variations) and MaatriSeq (Non-Invasive Prenatal Screening).
According to an official release, these innovations are tailored to the specific needs of the Indian community.
CNSeq brings the latest Next Generation Sequencing technology to an important prenatal test marking a significant leap forward in prenatal diagnostics. Leveraging proprietary software, CNSeq delivers unmatched precision in identifying Copy Number Variations (CNVs)...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.